Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: Example of complexed versus total prostate-specific antigen

Clinical Chemistry

Volumn 51, Issue 3, 2005, Pages 532-539

  Keller, Thomas ^a   Butz, Hermann ^b   Lein, Michael ^c   Kwiatkowski, Maciej ^d   Semjonow, Axel ^e   Luboldt, Hans Joachim ^f   Hammerer, Peter ^g   Stephan, Carsten ^c   Jung, Klaus ^c  

^a ACOMED Statistik   (Germany)

^b BAYER AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Kantonsspital Aarau ^*  (Switzerland)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CALCULATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISCORDANCE ANALYSIS CHARACTERISTICS METHOD; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; MULTICENTER STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

HUMANS; IMMUNOASSAY; MALE; MULTICENTER STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 14544286807     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.039552     Document Type: Article

References (24)

1. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine [Review]. Clin Chem 1993;39:561-77.
2. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
3. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
4. Obuchowski NA, Lieber ML, Wians FH. ROC curves in Clinical Chemistry: uses, misuses, and possible solutions. Clin Chem 2004;50:1118-25.
5. McClish DK. Analyzing a portion of the ROC curve. Med Decis Making 1989;9:190-5.
6. Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med 1997;16:1529-42.
7. Lein M, Kwiatkowski M, Semjonow A, Luboldt H-J, Hammerer P, Stephan C, et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003;170:1175-9.
8. Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002;60:31-5.
9. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection .in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001;165:1930-6.
10. Brawer MK, Meyer GE, Letran JL, Bankson ER, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-8.
11. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787-91.
12. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002;167:2017-23.
13. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed to total prostate specific antigen: which ratio should be determined to improve the differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000;46:55-62.
14. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-23.
15. Sturgeon C, Dati F, Duffy MJ, Hasholzner U, Klapdor R, Lamerz R, et al. European Group on Tumour Markers. Tumour marker recommendations. http://egtm.web.med.uni-muenchen.de/detail/1.htm (accessed September 2004).
16. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991:611pp.
17. Härdle W, Simar L. Applied multivariate analysis. Berlin: Springer, 2003:486pp.
18. Efron B, Tibshirani R. An introduction to the boostrap. New York: Chapman & Hall, 1993:436pp.
19. R Development Core Team. The R manuals, version 1.9.1. http://www.r-project.org (accessed September 2004).
20. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comp Graph Stat 1996;5:299-314.
21. Parsons JK, Partin AW. Applying complexed prostate-specific antigen to clinical practice. Urology 2004;63:815-8.
22. Okihara K, Ukimura O, Nakamura T, Mizutani Y, Naya Y, Uchida M, et al. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? Eur Urol 2004;46:57-64.
23. Biggerstaff BJ. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med 2000;19:649-63.
24. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 1983;21:709-20.